# Jinling Cohort (MERCURY multi-omic test in Nanjing)

Source: https://onco.cc/trials/jinling-cohort/  
OnCo record `jinling-cohort` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Chinese cohort of 15,000 people at average risk followed with a multi-omic blood test for several cancers.

## Summary

Jinling Cohort (NCT06011694) is an observational study sponsored by Nanjing Shihejiyin Technology, Inc. It is a prospective cohort study of the multi-omic liquid biopsy MCED test MERCURY in an average-risk Chinese population.

The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 15,000 participants, a start on 15 June 2022 and primary completion expected on 15 May 2027.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-29
- Also known as: Jinling Cohort; MERCURY
- Registry id: NCT06011694
- Phase: observational
- Setting: Adults aged 45 to 75 at average risk in Nanjing, China, followed with the MERCURY multi-omic blood test and annual check-ups
- Sponsor: Nanjing Shihejiyin Technology, Inc.
- Enrolled: 15000

## Sources

- ClinicalTrials.gov NCT06011694: https://clinicaltrials.gov/study/NCT06011694

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)

---
JSON: https://onco.cc/api/v1/entities/jinling-cohort.json